Azithromycin Towards COPD Assesment Test (CAT) for Stable Chronic Obstructive Pulmonary Disease


Hendri Nofa, Yusrizal Chan, Masrul Basyar, Oea Khairsyaf
Departemen Pulmonologi dan Ilmu Kedokteran Respirasi Fakultas Kedokteran Universitas Andalas, RSUP Dr. M. Djamil, Padang

Background: Azithromycin is a macrolide, that have antibiotic anti inflammation property that might decrease progresivity of chronic obstructive pulmonary disease (COPD). CAT is a simple questionnaire, useful and sensitive for the assesing effect of COPD toward health status. The aim of this study is to evaluate effect of 8 weeks azithromycin toward CAT scores.
Methods: Clinical study enrolled 25 stable COPD outpatients Dr. M. Djamil hospital in Padang between September 2013 and April 2014 who gave azithromycin 250 mg three times a weeks for 8 weeks. CAT scores was evaluated before and after treatment. Data of CAT before and after treatment was analyzed with t test.
Results: The mean age of the study is 69±6.9 years, degree of COPD predominantly was severe (64%) and CAT score was moderate (96%). Azithromycin decreased CAT score from 14.52 to 12.48 (p=0.019). CAT variable that significantly affected were cough, sputum, and chest tighness.
Conclusion: Azithromycin 250 mg for eight weeks affected decrease CAT scores. It influences cough, sputum production and tighness of chest significantly. (J Respir Indo. 2015; 35: 46-50)
Keywords: COPD, inflammation, macrolide, CAT scores.

Click here for full paper (PDF)